机构：[1]Department of Dermatology, the First Affiliated Hospital of Fujian Medical University, 20 Chazhong Road, Fuzhou, Fujian, China.[2]Department of Dermatology, Beijing Anzhen Nanchong Hospital, Capital Medical University & Nanchong Central Hospital, Nanchong, Sichuan, China.首都医科大学附属安贞医院[3]Fujian Dermatology and Venereology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.[4]Key Laboratory of Skin Cancer of Fujian Higher Education Institutions, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.[5]Central Laboratory, the First Affiliated Hospital of Fujian Medical University, 20 Chazhong Road, Fuzhou, Fujian, China.
Dear Editor, Janus kinase (JAK) inhibitors are considered the optimal systemic therapy for adults with severe alopecia areata (AA).1,2 Baricitinib, a JAK1/2 inhibitor, was the first systemic JAK inhibitor (JAKi) used for AA on-label. 1,2 However, some patients demonstrated an inadequate or no response to baricitinib.1,2 Subsequently, ritlecitinib, a JAK3/tyrosine kinase (TEC) inhibitor was approved for treating severe AA. 3 Currently, there are no reports addressing the efficacy of ritlecitinib in patient with inadequate or no response to baricitinib. To fill this gap, we conducted a retrospective case series to explore the efficacy and safety of switching from baricitinib to ritlecitinib in severe AA.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类|4 区医学
小类|4 区皮肤病学
第一作者：
第一作者机构：[1]Department of Dermatology, the First Affiliated Hospital of Fujian Medical University, 20 Chazhong Road, Fuzhou, Fujian, China.[2]Department of Dermatology, Beijing Anzhen Nanchong Hospital, Capital Medical University & Nanchong Central Hospital, Nanchong, Sichuan, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Dermatology, the First Affiliated Hospital of Fujian Medical University, 20 Chazhong Road, Fuzhou, Fujian, China.[3]Fujian Dermatology and Venereology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.[4]Key Laboratory of Skin Cancer of Fujian Higher Education Institutions, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
推荐引用方式(GB/T 7714)：
Chen Ying,Xu Qiuyun,Lv Xiaoqing,et al.Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata[J].Clinical And Experimental Dermatology.2024,doi:10.1093/ced/llae548.
APA：
Chen Ying,Xu Qiuyun,Lv Xiaoqing,Zhuang Zeyu,Bao Siyi...&Ji Chao.(2024).Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata.Clinical And Experimental Dermatology,,
MLA：
Chen Ying,et al."Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata".Clinical And Experimental Dermatology .(2024)
